183 related articles for article (PubMed ID: 35217681)
21. Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: a new approach for target discovery.
van der Sligte NE; Scherpen FJ; Meeuwsen-de Boer TG; Lourens HJ; Ter Elst A; Diks SH; Guryev V; Peppelenbosch MP; van Leeuwen FN; de Bont ES
Proteomics; 2015 Apr; 15(7):1245-54. PubMed ID: 25422122
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
23. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
[TBL] [Abstract][Full Text] [Related]
24. Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.
Li Y; Yang X; Sun Y; Li Z; Yang W; Ju B; Easton J; Pei D; Cheng C; Lee S; Pui CH; Yu J; Chi H; Yang JJ
Blood; 2022 Sep; 140(13):1507-1521. PubMed ID: 35675514
[TBL] [Abstract][Full Text] [Related]
25. Responsiveness to Hedgehog Pathway Inhibitors in T-Cell Acute Lymphoblastic Leukemia Cells Is Highly Dependent on 5'AMP-Activated Kinase Inactivation.
Tosello V; Bongiovanni D; Di Martino L; Franchin C; Zanovello P; Arrigoni G; Piovan E
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203724
[TBL] [Abstract][Full Text] [Related]
26. CBP Modulates Sensitivity to Dasatinib in Pre-BCR
Duque-Afonso J; Lin CH; Han K; Morgens DW; Jeng EE; Weng Z; Jeong J; Wong SHK; Zhu L; Wei MC; Chae HD; Schrappe M; Cario G; Duyster J; Xiao X; Sakamoto KM; Bassik MC; Cleary ML
Cancer Res; 2018 Nov; 78(22):6497-6508. PubMed ID: 30262461
[TBL] [Abstract][Full Text] [Related]
27. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
28. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A; Iacobucci I; Imbrogno E; Papayannidis C; Derenzini E; Ferrari A; Guadagnuolo V; Robustelli V; Parisi S; Sartor C; Abbenante MC; Paolini S; Martinelli G
Oncotarget; 2016 Aug; 7(33):53377-53391. PubMed ID: 27438145
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia.
He Y; Zhang J; Zhang Y; Hu Z; Wang P; Gan W; Xie S; Qian M; Pui CH; Jiang H; Zhu X; Zhang H; Zhang W
Pediatr Blood Cancer; 2022 Aug; 69(8):e29724. PubMed ID: 35441457
[TBL] [Abstract][Full Text] [Related]
32. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
34. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.
Laukkanen S; Grönroos T; Pölönen P; Kuusanmäki H; Mehtonen J; Cloos J; Ossenkoppele G; Gjertsen B; Øystein B; Heckman C; Heinäniemi M; Kontro M; Lohi O
Blood Cancer J; 2017 Sep; 7(9):e604. PubMed ID: 28885610
[No Abstract] [Full Text] [Related]
35. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
Front Immunol; 2018; 9():2433. PubMed ID: 30405627
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
37. Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
Vyse S; McCarthy F; Broncel M; Paul A; Wong JP; Bhamra A; Huang PH
J Proteomics; 2018 Jan; 170():130-140. PubMed ID: 28842319
[TBL] [Abstract][Full Text] [Related]
38. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Ren M; Qin H; Ren R; Tidwell J; Cowell JK
Cancer Res; 2011 Dec; 71(23):7312-22. PubMed ID: 21937681
[TBL] [Abstract][Full Text] [Related]
39. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Rexer BN; Ham AJ; Rinehart C; Hill S; Granja-Ingram Nde M; González-Angulo AM; Mills GB; Dave B; Chang JC; Liebler DC; Arteaga CL
Oncogene; 2011 Oct; 30(40):4163-74. PubMed ID: 21499296
[TBL] [Abstract][Full Text] [Related]
40. Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
Hallal M; Braga-Lagache S; Jankovic J; Simillion C; Bruggmann R; Uldry AC; Allam R; Heller M; Bonadies N
BMC Cancer; 2021 Jul; 21(1):789. PubMed ID: 34238254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
